The Use of Gene Expression Profiling and Biomarkers in Melanoma Diagnosis and Predicting Recurrence: Implications for Surveillance and Treatment

Author:

Sun James1ORCID,Karasaki Kameko M.2,Farma Jeffrey M.1ORCID

Affiliation:

1. Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19002, USA

2. Department of Surgery, University of Hawaii, Honolulu, HI 96813, USA

Abstract

Cutaneous melanoma is becoming more prevalent in the United States and has the highest mortality among cutaneous malignancies. The majority of melanomas are diagnosed at an early stage and, as such, survival is generally favorable. However, there remains prognostic uncertainty among subsets of early- and intermediate-stage melanoma patients, some of whom go on to develop advanced disease while others remain disease-free. Melanoma gene expression profiling (GEP) has evolved with the notion to help bridge this gap and identify higher- or lower-risk patients to better tailor treatment and surveillance protocols. These tests seek to prognosticate melanomas independently of established AJCC 8 cancer staging and clinicopathologic features (sex, age, primary tumor location, thickness, ulceration, mitotic rate, lymphovascular invasion, microsatellites, and/or SLNB status). While there is a significant opportunity to improve the accuracy of melanoma prognostication and diagnosis, it is equally important to understand the current landscape of molecular profiling for melanoma treatment. Society guidelines currently do not recommend molecular testing outside of clinical trials for melanoma clinical decision making, citing insufficient high-quality evidence guiding indications for the testing and interpretation of results. The goal of this chapter is to review the available literature for GEP testing for melanoma diagnosis and prognostication and understand their place in current treatment paradigms.

Publisher

MDPI AG

Reference64 articles.

1. National Cancer Institute (2023, December 24). Cancer Stat Facts: Melanoma of the Skin. Bethesda, MD, USA, Available online: https://seer.cancer.gov/statfacts/html/melan.html.

2. National Comprehensive Cancer Network (2023, December 24). Clinical Practice Guidelines in Oncology Melanoma: Cutaneous Version 2.2023. Available online: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf.

3. Gene expression detection assay for cancer clinical use;Narrandes;J. Cancer,2018

4. Guidelines of care for the management of primary cutaneous melanoma;Swetter;J. Am. Acad. Dermatol.,2019

5. Gene Expression Profiles in Cutaneous Oncology;Kitrell;Dermatol. Clin.,2023

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3